During the last session, Replimune Group Inc (NASDAQ:REPL)’s traded shares were 0.73 million, with the beta value of the company hitting 1.31. At the end of the trading day, the stock’s price was $13.59, reflecting an intraday loss of -1.16% or -$0.16. The 52-week high for the REPL share is $17.00, that puts it down -25.09 from that peak though still a striking 63.8% gain since the share price plummeted to a 52-week low of $4.92. The company’s market capitalization is $1.02B, and the average intraday trading volume over the past 10 days was 0.98 million shares, and the average trade volume was 864.08K shares over the past three months.
Replimune Group Inc (REPL) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.12. REPL has a Sell rating from 0 analyst(s) out of 5 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 5 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.72.
Replimune Group Inc (NASDAQ:REPL) trade information
Replimune Group Inc (REPL) registered a -1.16% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -1.16% in intraday trading to $13.59, hitting a weekly high. The stock’s 5-day price performance is 31.18%, and it has moved by 8.81% in 30 days. Based on these gigs, the overall price performance for the year is 72.90%. The short interest in Replimune Group Inc (NASDAQ:REPL) is 6.61 million shares and it means that shorts have 8.77 day(s) to cover.
The consensus price target of analysts on Wall Street is $23, which implies an increase of 40.91% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $19 and $27 respectively. As a result, REPL is trading at a discount of -98.68% off the target high and -39.81% off the low.
Replimune Group Inc (REPL) estimates and forecasts
Statistics show that Replimune Group Inc has underperformed its competitors in share price, compared to the industry in which it operates. Replimune Group Inc (REPL) shares have gone up 32.59% during the last six months, with a year-to-date growth rate less than the industry average at 11.11% against 16.50.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -19.52%. While earnings are projected to return 15.48% in 2025, the next five years will return 13.46% per annum.
REPL Dividends
Replimune Group Inc is due to release its next quarterly earnings in February. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Replimune Group Inc (NASDAQ:REPL)’s Major holders
Replimune Group Inc insiders own 4.18% of total outstanding shares while institutional holders control 92.48%, with the float percentage being 96.52%. BAKER BROS. ADVISORS LP is the largest shareholder of the company, while 210.0 institutions own stock in it. As of 2024-06-30, the company held over 10.05 million shares (or 15.0899% of all shares), a total value of $90.41 million in shares.
The next largest institutional holding, with 9.24 million shares, is of PRICE T ROWE ASSOCIATES INC /MD/’s that is approximately 13.8742% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $83.13 million.
Also, the Mutual Funds coming in first place with the largest holdings of Replimune Group Inc (REPL) shares are Price (T.Rowe) New Horizons Fund and Vanguard Total Stock Market Index Fund . Data provided on Sep 30, 2024 indicates that Price (T.Rowe) New Horizons Fund owns about 4.39 shares. This amounts to just over 6.42 percent of the company’s overall shares, with a $59.7 million market value. The same data shows that the other fund manager holds slightly less at 2.02, or about 2.96% of the stock, which is worth about $27.5 million.
